Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Behav Brain Res ; 465: 114963, 2024 May 08.
Artigo em Inglês | MEDLINE | ID: mdl-38499158

RESUMO

Lisdexamfetamine (LDX) is one of the drugs commonly used to treat attention deficit hyperactivity disorder (ADHD). However, its neurological side effects, particularly on cognition, are not fully understood. The present study focused on memory in rats treated with four weeks of LDX injection. We compared LDX-treated rats with control ones, using several methods to evaluate the behavioral responses and electrophysiological, molecular, and histological properties in the hippocampus. Our findings demonstrated that subchronic administration of LDX impaired behavioral performance in all memory assessment tests (Y maze, Morris Water Maze, and Shuttle box). Although LDX did not alter population spike (PS) amplitude, it increased the field excitatory postsynaptic potential (fEPSP) slope of evoked potentials of LTP components. Also, in addition to an increase in expression of caspase-3 in the hippocampus, which indicates the susceptibility to apoptosis in LDX-treated rats, the number of microglia and astrocytes went up significantly in the LDX group. Moreover, Sholl's analysis showed an increase in the soma size and total process length in both hippocampal astrocytes and microglia. Overall, because of these destructive effects of LDX on the hippocampus, which is one of the critical memory-related areas of the brain, the findings of this investigation provide evidence to show the disruption of memory-related variables following the LDX. However, more research is needed to clarify it.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade , Estimulantes do Sistema Nervoso Central , Ratos , Animais , Dimesilato de Lisdexanfetamina/uso terapêutico , Dextroanfetamina , Resultado do Tratamento , Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Amnésia/induzido quimicamente , Estimulantes do Sistema Nervoso Central/farmacologia , Método Duplo-Cego
2.
Reprod Sci ; 31(5): 1278-1289, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38228974

RESUMO

Concerns have been raised about potentially irreversible brain damage and damage to the neuroendocrine system during development when treating attention-deficit/hyperactivity disorder with lisdexamfetamine (LDX), a norepinephrine dopamine reuptake inhibitor. This study aims to elucidate the potential adverse effects of LDX on the male reproductive system due to its widespread use and potential for abuse. In this study, adult male rats were randomized into control and LDX groups. Thirty milligrams per kilogram LDX was administered orally for 3 weeks. After isolation of epididymal spermatozoa, the rats were euthanized and testicular tissues were collected for stereological and molecular analyses. The LDX group showed a decrease in sperm motility and an increase in DNA fragmentation compared to the control group. There was also a dramatic decrease in testosterone in the LDX group. Testicular expression of caspase-3 and TNF-α was significantly increased in the LDX group. According to our findings, prolonged use of LDX leads to reduced sperm quality. It also induces apoptosis, inflammatory response, and pathological changes in the testicular tissue. What we have observed in this study is noteworthy but requires further investigation, particularly in people who use LDX over a longer period of time.


Assuntos
Apoptose , Dimesilato de Lisdexanfetamina , Motilidade dos Espermatozoides , Espermatozoides , Testículo , Animais , Masculino , Apoptose/efeitos dos fármacos , Espermatozoides/efeitos dos fármacos , Espermatozoides/patologia , Dimesilato de Lisdexanfetamina/toxicidade , Testículo/efeitos dos fármacos , Testículo/patologia , Testículo/metabolismo , Motilidade dos Espermatozoides/efeitos dos fármacos , Ratos Sprague-Dawley , Inflamação/induzido quimicamente , Inflamação/patologia , Ratos , Testosterona , Fragmentação do DNA/efeitos dos fármacos , Caspase 3/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA